SynthesisFrontiers in medicine2026
A systematic review of semaglutide-associated kidney injury case reports.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although semaglutide is widely used due to its efficacy in glycemic control and weight reduction, cases of the associated adverse drug reactions (ADRs), including kidney injury, have gradually increased. This systematic review aimed to summarize reported cases and case series of semaglutide-associated renal injury and their clinical and laboratory features. Methods: Case reports and case series on ADRs associated with semaglutide published in English and Chinese were systematically retrieved using relevant keywords from PubMed/MEDLINE, Web of Science, Embase, the Cochrane Library, and the Chinese National Knowledge Infrastructure (CNKI) database from database inception to October 31, 2025. Demographic characteristics, clinical information, ADRs, kidney-related laboratory tests, and outcomes were extracted. We used the Joanna Briggs Institute Critical Appraisal Checklist for Case Reports (JBI Case Report Checklist) to evaluate the quality of each included study. Results: A total of 20 cases (7 males and 13 females) from 18 studies were included after screening 1039 selected publications, with patient ages ranging from 29 to 83 years. Most patients received semaglutide via subcutaneous injection for weight loss or blood sugar reduction. Except for one case with unknown history, all patients had a pre-existing medical condition and were receiving concomitant medications. ADRs occurred at the standard recommended dose, ranging from 0.25 to 2.0 mg and included acute kidney injury (AKI), acute renal failure (ARF), and acute interstitial nephritis (AIN). Twelve cases were diagnosed through renal biopsy, and the remaining eight cases were diagnosed based on renal function parameters. The dosage varied from 0.25 to 2.0 mg per week. The majority of patients developed ADRs after multiple administrations. The clinical manifestations of the patients were diverse. Following treatment, 17 patients improved or recovered, outcomes were not reported in two patients, and one patient did not recover. Conclusion: Semaglutide use may be associated with kidney damage, which may be irreversible. Clinicians should be cautious when prescribing semaglutide to individuals with underlying conditions and those receiving concomitant medications, and should ensure regular monitoring of kidney function after treatment initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.